AURA — Aura Biosciences, Inc. stock price, charts and financials

QT70Aura Biosciences, Inc.

Aura Biosciences, Inc. (NASDAQ: AURA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
7.66
-0.33-4.10%
OverviewShort InterestFilings
AURAQT70Aura Biosciences, Inc.·NASDAQ
7.66-4.10%
Earnings
Down 4.1% — Earnings due 2026-08-12 — pre-report positioning.
Medium confidence
TA
Loading chart...
Screen all →
AUPH-2.45%$15.46MESO+4.71%$16.69ZBIO-0.83%$32.16GHRS-1.62%$29.78TSHA-1.51%$6.46STOK-1.22%$32.31ABCL+39.97%$9.70VRDN-3.29%$22.81
Snapshot
Index-P/E-EPS (ttm)-Insider Own28.19%Shs Outstand103.44MPerf Week13.98%
Market Cap826.46MForward P/E-EPS next Y-1.67Insider Trans-38.96%Shs Float64.51MPerf Month14.14%
Enterprise Value758.65MPEG-EPS next Q-Inst Own-Short Float8.69%Perf Quarter-2.56%
Income-172.40MP/S0.00EPS this Y-Inst Trans-Short Ratio8.63Perf Half Y49.07%
Sales0.00P/B5.02EPS next Y-4.55%ROA-81.64%Short Interest5.61MPerf YTD46.61%
Book/sh-P/C-EPS next 5Y-ROE-78.12%52W High9.15 -16.25%Perf Year16.81%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-95.48%52W Low4.54 68.92%Perf 3Y-29.29%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility4.41% 4.41%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM0.57%Oper. Margin0.00%ATR (14)0.34Perf 10Y-
Dividend Ex-Date-Quick Ratio7.09Sales Y/Y TTM-Profit Margin0.00%RSI (14)69.16Recom2.00
Dividend Gr. 3/5Y-Current Ratio7.09EPS Q/Q9.09%SMA2012.20%Beta1.20Target Price17.00
Payout0.00%Debt/Eq0.16Sales Q/Q-SMA5015.04%Rel Volume0.98Prev Close7.99
Employees113LT Debt/Eq0.10EarningsAug 12SMA20024.72%Avg Volume548.57KPrice7.66
IPO DateOct 29, 2021Option/ShortYes / YesEPS/Sales Surpr.-25.79% -Net Debt/EBITDA0.61Volume537,903Change-4.10%
Analyst Ratings
DateActionAnalystRatingTarget
May-12-26ReiteratedLeerink Partners$26 → $17
Mar-26-25ReiteratedJMP SecuritiesMarket Outperform$30 → $19
Mar-25-25ReiteratedHC Wainwright & Co.Buy$22 → $25
Mar-24-25ReiteratedHC Wainwright & Co.Buy$22 → $25
Oct-18-24ReiteratedBTIGBuy$24
Oct-18-24ReiteratedScotiabankSector Outperform$23
Oct-18-24ReiteratedHC Wainwright & Co.Buy$21 → $22
Jul-25-24InitiatedH.CBuy$21
Nov-11-22ReiteratedJMP SecuritiesMarket Outperform$30
Latest News
Company

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000————
Cost of Goods Sold Incl. D&A001————
Gross Profit00-1————
Selling, General and Administrative Excl. Other222320————
Research and Development907364————
Other Operating Expense100————
Operating Income-113-96-85————
Interest Expense
000————
Unusual Expense
———————
Non-Operating Income (Expense)799————
Net Income Before Taxes-106-87-76————
Income Taxes
000————
Consolidated Net Income-106-87-76————
Net Income From Continuing Operations-106-87-76————
Net Income-106-87-76————
EPS (Recurring)-1.76-1.75-1.93————
EPS (Basic, Before Extraordinaries)-1.76-1.75-1.93————
EPS (Diluted)-1.76-1.75-1.93————
EBITDA-105-86-75————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding605040————
Market Capitalization327411354————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$9.49$8.21$6.93$5.66$4.38● Close Price0.00M9.76M19.52M29.28M39.04MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Gibney Anthony SSee RemarksJun 16 '26Sale6.4212,82482,330265,354Jun 16
Matrix Capital Management Company, LP10% OwnerMay 07 '26Sale5.646,922,87039,044,9870May 11
Kilroy ConorSee RemarksApr 16 '26Sale7.0211,73882,401217,835Apr 16
Kilroy ConorSee RemarksFeb 17 '26Sale5.0512,07960,999167,234Feb 17
Plavsic MarkChief Technology OfficerFeb 17 '26Sale5.0515,89080,245181,397Feb 17
Hopkins Janet JillChief Medical OfficerFeb 17 '26Sale5.0620,401103,229232,284Feb 17
Elazzouzi AmySenior Vice President, FinanceFeb 17 '26Sale5.068,54943,25875,532Feb 17
de los Pinos ElisabetSee RemarksFeb 17 '26Sale5.0647,648241,099409,815Feb 17
Elazzouzi AmySenior Vice President, FinanceJan 20 '26Sale4.861,5817,68484,081Jan 20
de los Pinos ElisabetSee RemarksJan 20 '26Sale4.8616,92882,270457,463Jan 20
Hopkins Janet JillChief Medical OfficerNov 17 '25Sale5.4217,10992,731252,685Nov 17
Elazzouzi AmySenior Vice President, FinanceOct 29 '25Sale6.358965,69085,662Oct 29
de los Pinos ElisabetSee RemarksOct 29 '25Sale6.359,04957,461474,391Oct 29
Plavsic MarkChief Technology OfficerOct 16 '25Sale6.3512,16977,273197,287Oct 16
Elazzouzi AmySenior Vice President, FinanceAug 18 '25Option Exercise3.9612,89951,10494,280Aug 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.